ObjectiveTo evaluate the use of the SurgiLance® SLN100 safety lancet with patients living with diabetes, evaluating whether an adequate blood sample is obtained and comparing the level of pain to the patient’s own lancing device.
A total of 200 patients were tested. Of them, 198 had diabetes: 164 had been diagnosed with Type 2 diabetes and 34 with Type 1 diabetes. Patient included 87 males and 113 females ranging in age from 23 to 87. Patient skin condition ranged from thin (18%) to normal (74%) to calloused (8%). Patients were evaluated over the course of one week in July 2007 at the Richmond, Virginia (US) offices of Diabetes, Endocrine, and Internal Medicine Associates.
The SurgiLance® SLN100 delivered an adequate blood sample for 92% of all patients on the first attempt. In addition, the SurgiLance® SLN100 safety lancet was considered less painful than the lancing device most frequently used for 80% of those patients tested and equally painful to their current device for 19% of the patient population.
The required blood sample was obtained with a total of 92% of patients. Among the small percentage of patients for whom the required sample was not obtained with the SurgiLance® safety lancets, all had calloused fingers.
An overwhelming 99% of all patients stated that the SurgiLance® safety lancet was less painful than (80%) or equally painful to (19%) the current lancing device they used for blood glucose testing.
The SurgiLance® SLN100 safety lancet is a 1.00 mm depth needle lancet capable of delivering a blood flow of 5-10 microliters. Most commonly used for a finger stick blood glucose test, the SLN100 features an improved, high-speed delivery system that minimizes patient pain and discomfort. Often preferred for use with young children and elderly patients with thin skin, the SLN100 has been used in pediatrics wards, WIC clinics and children’s hospitals as well as in alternate care and extended living facilities.
© 2012 MediPurpose Private Limited | About Us | Contact Us | Terms of Use
Join MediPurpose on 
